tetano
Editor, Senior Moderator
Respir Med Case Rep
. 2024 Sep 2:51:102104.
doi: 10.1016/j.rmcr.2024.102104. eCollection 2024. Protracted coronavirus disease 2019 after chimeric antigen receptor-T cell therapy successfully treated with sequential multidrug therapy
Masahiro Yamashita[SUP] 1 [/SUP], Hisao Higo[SUP] 1 [/SUP], Nobuharu Fujii[SUP] 2 [/SUP], Chiaki Matsumoto[SUP] 1 [/SUP], Go Makimoto[SUP] 1 [/SUP], Kiichiro Ninomiya[SUP] 3 [/SUP], Masanori Fujii[SUP] 1 [/SUP], Kammei Rai[SUP] 4 [/SUP], Eiki Ichihara[SUP] 5 [/SUP], Kadoaki Ohashi[SUP] 1 [/SUP], Katsuyuki Hotta[SUP] 4 [/SUP], Masahiro Tabata[SUP] 5 [/SUP], Yoshinobu Maeda[SUP] 6 [/SUP], Nobuaki Miyahara[SUP] 1 7 [/SUP]
Affiliations
A 56-year-old woman who received CD19 chimeric antigen receptor-T cell therapy for refractory diffuse large B-cell lymphoma developed severe coronavirus disease 2019 (COVID-19) and was treated with nirmatrelvir/ritonavir in April 2022. However, she experienced persistent fatigue and cough and fever in June. Computed tomography revealed bilateral ground-glass opacities (GGO), and the patient was treated with corticosteroids for organizing pneumonia after COVID-19. Partial improvement was observed, but new GGO appeared despite corticosteroid therapy. Genome analysis of severe acute respiratory syndrome coronavirus 2 detected Omicron variant BA.1.1.2, which was prevalent at the time of initial infection. The patient was diagnosed with protracted COVID-19 and was treated with remdesivir, molnupiravir, nirmatrelvir/ritonavir, and tixagevimab/cilgavimab. These treatments appeared to contribute to the improvement of protracted COVID-19.
Keywords: Chimeric antigen receptor-T cell therapy; Coronavirus disease 2019; Multidrug therapy; Organizing pneumonia.
. 2024 Sep 2:51:102104.
doi: 10.1016/j.rmcr.2024.102104. eCollection 2024. Protracted coronavirus disease 2019 after chimeric antigen receptor-T cell therapy successfully treated with sequential multidrug therapy
Masahiro Yamashita[SUP] 1 [/SUP], Hisao Higo[SUP] 1 [/SUP], Nobuharu Fujii[SUP] 2 [/SUP], Chiaki Matsumoto[SUP] 1 [/SUP], Go Makimoto[SUP] 1 [/SUP], Kiichiro Ninomiya[SUP] 3 [/SUP], Masanori Fujii[SUP] 1 [/SUP], Kammei Rai[SUP] 4 [/SUP], Eiki Ichihara[SUP] 5 [/SUP], Kadoaki Ohashi[SUP] 1 [/SUP], Katsuyuki Hotta[SUP] 4 [/SUP], Masahiro Tabata[SUP] 5 [/SUP], Yoshinobu Maeda[SUP] 6 [/SUP], Nobuaki Miyahara[SUP] 1 7 [/SUP]
Affiliations
- PMID: 39286407
- PMCID: PMC11404050
- DOI: 10.1016/j.rmcr.2024.102104
A 56-year-old woman who received CD19 chimeric antigen receptor-T cell therapy for refractory diffuse large B-cell lymphoma developed severe coronavirus disease 2019 (COVID-19) and was treated with nirmatrelvir/ritonavir in April 2022. However, she experienced persistent fatigue and cough and fever in June. Computed tomography revealed bilateral ground-glass opacities (GGO), and the patient was treated with corticosteroids for organizing pneumonia after COVID-19. Partial improvement was observed, but new GGO appeared despite corticosteroid therapy. Genome analysis of severe acute respiratory syndrome coronavirus 2 detected Omicron variant BA.1.1.2, which was prevalent at the time of initial infection. The patient was diagnosed with protracted COVID-19 and was treated with remdesivir, molnupiravir, nirmatrelvir/ritonavir, and tixagevimab/cilgavimab. These treatments appeared to contribute to the improvement of protracted COVID-19.
Keywords: Chimeric antigen receptor-T cell therapy; Coronavirus disease 2019; Multidrug therapy; Organizing pneumonia.